Governance

As a publicly funded entity and a national drug development platform, EDDC’s Governing Board comprises members from key public agencies as well as former industry veterans.

Chairpersons

[B] William-Chin-Emeritus-Bertarelli-Prof-Harvard-Medical-School

Prof. William Chin
Co-Chair

Emeritus Bertarelli Professor
of Translational Medical Science
Harvard Medical School

Formerly SVP Discovery Research, Eli Lilly

[B] Benjamin-Seet-Group-Chief-Research-Officer-National-Healthcare-Group

Prof. Benjamin Seet
Co-Chair

Group Chief Research Officer
National Healthcare Group



Members

Damian-O'Connell-CEO-EDDC
Dr Damian O’Connell
Chief Executive Officer, Experimental Drug Development Centre (EDDC), A*STAR

Tan-Sze-Wee-ACE-Enterprise-ASTAR
Prof Tan Sze Wee
Assistant Chief Executive, Enterprise, A*STAR

Beh-Kian-Teik-Depeuty-CEO-NRF-3
Mr Beh Kian Teik
Deputy Chief Executive Officer, National Research Foundation (NRF)

Lisa-Ooi-VP-Strategy (health and awreness)-EDB-1
Dr Lisa Ooi
Vice President, Strategy (Health and Wellness), Economic Development Board (EDB)

Danny-Soon-CEO-CRIS
Dr Danny Soon
Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore (CRIS), MOH

Tan-Say-Beng-ED-NMRC
A/Prof Tan Say Beng
Executive Director, National Medical Research Council (NMRC)

Ng-Huck-Hui-ACE-BMRC
Prof Ng Huck Hui
Assistant Chief Executive Biomedical Research Council (BMRC), A*STAR


Audrey-Lok-Director-Food-Healthcare-&-Biomedical-ESG
Audrey Lok
Director, Healthcare & Biomedical, Enterprise Singapore (ESG)

Andreas-Wallnoefer-General-Partner-Biomed-Partners-AG
Dr Andreas Wallnoefer
General Partner,   
BioMedPartners AG
Former SVP & Global Head of Development, Hoffman-La Roche

Portfolio Review Committee (PRC)
EDDC’s portfolio projects and platforms are reviewed by a PRC, comprising industry veterans and eminent scientists. The PRC also provides advice and recommendations to the Governing Board.